CA-125 in fine-needle aspirates of solid tumors: Comparison with cytologic diagnosis and carcinoembryonic antigen (CEA) assay

Abstract

One hundred and twenty‐two fine needle aspirates (FNA) from female patients were studied to determine whether CA‐125 assay contributed to cytologic diagnosis and CEA assay. Cytologic examination was done on Papanicolaou‐stained smears and cell blocks, CEA by EIA (Abbott Laboratory, > 5 ng/ml cutoff) and CA‐125 by RIA (Abbott Laboratory, North Chicago, IL, > 66 μ/ml cutoff). Final diagnosis were correlated with histologic diagnosis when available, clinical, radiologic studies, and follow‐up. Results: 29 benign, 93 malignant. Sensitivities and specificities: cytology, 91%, 100%; CEA: 59%, 86%; CA‐125, 50%, 55%. CEA plus cytology sensitivity, 97%. CA‐125 content was highest in endometrial/ovarian carcinoma (39,899 μ/ml) and < 5,000 μ/ml in other tumors and benign FNA in contrast to CEA which showed highest levels in carcinomas of colon, pancreas, and lung (> 280 ng/ml). While elevated CEA enhances the sensitivity of cytologic diagnosis of carcinomas of the colon, pancreas, and lung, low CEA and high CA‐125 content supports an ovarian/endometrial primary. Diagn Cytopathol 1996;14:121–125. © 1996 Wiley‐Liss, Inc.

ACG Clinical Guideline: Focal Liver Lesions

“…Complete surgical resection, either by laparoscopic or open method, is the gold standard for all MCNs, given high rate of recurrence or progression to cystadenocarcinoma with incomplete resection (246,(262)(263)(264)(265)(266). Other modalities including cyst aspiration, sclerosis, partial resection, or cyst fenestration are not recommended because of the high rate of recurrence, reported at 81% in some studies (246,(267)(268)(269)(270). Therefore, for patients who are not surgical candidates, surveillance imaging is recommended, although there are no established guidelines regarding specific intervals.…”